Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-Acetylcysteine for Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer
NCT07391163Completed
- Sponsor
- Tanta University
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing NAC Group with Placebo Group (2 arms). Primary endpoints: National Cancer Institute Common Terminology Criteria for Adverse Events Version 5 at 29 days, Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity 12 at 29 days and 1 more. Started Jan 2024; status: completed.
02
Drugs
acetylcysteine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT07391163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07391163.